Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457580 | 0.95 | GSK3B (0.35) | LRRK2MAPK1NTRK1ACACBGSK3B | |
| SCHEMBL17457575 | 0.85 | LRRK2 (0.38) | LRRK2MAPK1NTRK1ACACBGSK3B | |
| SCHEMBL17457579 | 0.80 | GSK3B (0.37) | LRRK2MAPK1NTRK1ACACBGSK3B | |
| SCHEMBL16100558 | 0.74 | LRRK2 (0.41) | LRRK2MAPK1NTRK1GSK3BKCNH2 | |
| SCHEMBL16102326 | 0.74 | LRRK2 (0.40) | LRRK2MAPK1NTRK1ACACBGSK3B | |
| SCHEMBL16102325 | 0.74 | LRRK2 (0.39) | LRRK2MAPK1NTRK1GSK3BKCNH2 | |
| SCHEMBL16120036 | 0.73 | LRRK2 (0.44) | LRRK2MAPK1NTRK1SOS1 | |
| SCHEMBL16099442 | 0.70 | LRRK2 (0.47) | LRRK2MAPK1NTRK1SOS1 | |
| SCHEMBL16100245 | 0.69 | LRRK2 (0.38) | LRRK2MAPK1NTRK1GSK3BKCNH2 | |
| SCHEMBL16099650 | 0.69 | LRRK2 (0.36) | LRRK2MAPK1NTRK1GSK3BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | LRRK2 972/4885MAPK1 2610/4885NTRK1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.